Clinical Trials

Numerous clinical trials evaluate interventions across diverse indications, including neurodegenerative conditions such as Alzheimer's disease and dementia with Lewy bodies, bacterial infections, hypercholesterolemia, and cardiometabolic syndrome. Spanning early Phase 1 through Phase 4, these studies encompass active recruitment, completed evaluations, and not-yet-recruiting statuses. Sponsorship is provided by a mix of academic medical centers, such as Assistance Publique - Hôpitaux de Paris and the University of Iowa, and commercial entities like Organon and Co.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07354347 RECRUITING
Heart Disease; Implantable Cardioverter Defibrillator (ICD); Heart Rhythm Disorders; Ventricular Tachyarrhythmias
Rigshospitalet, Denmark
 2026-02-01
NCT06924073 RECRUITING
Adolescent HIV Infection; Transition to Adult Care; Implementation Science; Implementation Strategies
University of Washington
 2025-10-16
NCT06942572 RECRUITING
Stargardt Disease; Stargardt Macular Degeneration; Stargardt Macular Dystrophy
Splice Bio
 2025-02-11 PHASE1; PHASE2
NCT07167966 ENROLLING_BY_INVITATION
Preclinical Alzheimer's Disease; Prodromal Alzheimer's Disease; Alzheimer Disease
Paul S. Aisen
 2026-11-03 PHASE2
NCT06921720 RECRUITING
Phosphate Diabetes; X-linked Hypophosphatemia
Hospices Civils de Lyon
 2025-05-16
NCT07296354 NOT_YET_RECRUITING
Neuropathic Pain
Egyptian International Pharmaceutical Industries Co
 2026-01-10 PHASE4
NCT07214636 NOT_YET_RECRUITING
Apnea, Obstructive; Exercise Addiction; Physiotherapy and Rehabilitation
Medipol University
 2026-07-28
NCT07224269 RECRUITING
Amyotrophic Lateral Sclerosis; Adenosine Triphosphate Activities
University of Iowa
 2026-08-12 EARLY_PHASE1
NCT05458284 ACTIVE_NOT_RECRUITING
Breast Cancer; Taxane-Induced Peripheral Neuropathy
Memorial Sloan Kettering Cancer Center
 2022-07-11 PHASE2
NCT06266715 RECRUITING
Depression
Nanfang Hospital, Southern Medical University
 2024-03-04
NCT05734196 ACTIVE_NOT_RECRUITING
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic Rickets; Generalized Arterial Calcification of Infancy; ATP-Binding Cassette Subfamily C Member 6 Deficiency; Pseudoxanthoma Elasticum
Inozyme Pharma
 2023-06-25 PHASE1
NCT07085975 RECRUITING
Chronic Cough (CC); Asthma
McMaster University
 2025-08-05 PHASE1
NCT06523504 RECRUITING
Myopia
Ruihua Wei
 2024-02-01 PHASE1; PHASE2
NCT05627479 WITHDRAWN
Femoral Shaft Fracture; Tibial Shaft Fracture
NYU Langone Health
 2024-12-01 PHASE2
NCT05431413 UNKNOWN
Depression
Nanfang Hospital, Southern Medical University
 2020-01-07 PHASE2
NCT04096625 UNKNOWN
Psychiatric Disorder
Psychiatric University Hospital, Zurich
 2023-09-01
NCT06873828 NOT_YET_RECRUITING
Hypertrophic Cardiomyopathy
Yonsei University
 2025-03 PHASE3
NCT07585448 COMPLETED
Oral Hygiene; Visually Impaired Persons
Mahidol University
 2025-06-09
NCT04754581 ACTIVE_NOT_RECRUITING
Type 2 Diabetes
AdventHealth Translational Research Institute
 2021-03-30
NCT04099940 UNKNOWN
Psychosis; Schizophrenia; Schizo Affective Disorder; Hearing Voices When No One is Talking (Symptom)
Psychiatric University Hospital, Zurich
 2021-07-01
NCT05384860 COMPLETED
Acupuncture; Hip Surgery; Opioid Use
Hospital for Special Surgery, New York
 2022-07-06
NCT05495074 COMPLETED
Metabolic Syndrome
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
 2021-08-02
NCT04760860 Not yet recruiting
Dementia With Lewy Bodies
Qiang Zhang|University of Iowa
 2024-10 Phase 1|Phase 2
NCT06785558 COMPLETED
Overactive Bladder (OAB)
Marmara University
 2024-01-01
NCT05590195 Not yet recruiting
Bacterial Vaginosis|Bacterial Infections|Bacterial Vaginosis | Vaginal | Microbiology|Vaginal Infection
Jeremy Burton|Deerland Enzymes|Lawson Health Research Institute|St. Joseph''s Health Care London
 2024-05-01 Phase 3
NCT06167512 Not yet recruiting
Multi-organ Failure After Severe Trauma
Assistance Publique - Hôpitaux de Paris
 2024-04-01 --
NCT05713019 UNKNOWN
Cough
Imperial College London
 2023-02-28
NCT05791032 COMPLETED
Ventricular Arrythmia; Ventricular Tachycardia; Ventricular Fibrillation
AtaCor Medical, Inc.
 2023-09-05
NCT05565001 UNKNOWN
Headache; Migraine With Aura; Migraine Without Aura
Danish Headache Center
 2022-09-01
NCT02923726 COMPLETED
Sudden Cardiac Death
Boston Scientific Corporation
 2016-09-30
NCT05784610 UNKNOWN
Neuromuscular Blockade
Poitiers University Hospital
 2022-11-01
NCT05641454 COMPLETED
Caffeine and Endurance Performance
University of Exeter
 2022-10-17
NCT04857268 UNKNOWN
Atrial Fibrillation New Onset
Seoul National University Bundang Hospital
 2020-11-13
NCT06284005 COMPLETED
Amputation; Traumatic Amputation; Leg Injury; Lower Limb Injury
Fondazione Don Carlo Gnocchi ETS
 2020-07-27
NCT05243953 COMPLETED
Post-Traumatic Headache
Danish Headache Center
 2022-03-21
NCT03722849 COMPLETED
Cough
Stuart Mazzone
 2019-03-01
NCT05100589 COMPLETED
Cognitive Change; Mood
University of Central Florida
 2021-10-06
NCT05079529 UNKNOWN
Cardiometabolic Syndrome
University of Brawijaya
 2021-06-30 PHASE2
NCT03738943 COMPLETED
Receptor Blockade
Colorado State University
 2019-02-07 EARLY_PHASE1
NCT04489511 COMPLETED
Stargardt Disease-1
Stargazer Pharmaceuticals, Inc.
 2020-10-01 PHASE2
NCT02243631 COMPLETED
Calcium Pyrophosphate Deposition Disease
VA Office of Research and Development
 2014-10-15 EARLY_PHASE1
NCT04261881 COMPLETED
Fatigue
Natural Immune Systems Inc
 2018-03-27
NCT03775902 COMPLETED
Insulin Resistance
University of Copenhagen
 2018-12-19
NCT03138681 UNKNOWN
Major Depressive Disorder
Zhujiang Hospital
 2017-05-03 PHASE2
NCT03404843 COMPLETED
Cardiovascular Diseases
Colorado State University
 2017-07-14 PHASE2
NCT03119818 COMPLETED
End-Stage Renal Disease (ESRD)
Hospices Civils de Lyon
 2017-06-14
NCT01477983 COMPLETED
Atrial Fibrillation
Kyoto University, Graduate School of Medicine
 2011-11 PHASE4
NCT04681924 COMPLETED
Metabolic Syndrome
Hawler Medical University
 2017-01-01
NCT02439424 UNKNOWN
Atrial Tachyarrhythmia; Atrial Fibrillation
Hartford Hospital
 2015-12 PHASE1; PHASE2
NCT01824173 COMPLETED
Obesity
Mayo Clinic
 2012-10 PHASE1
NCT02286778 COMPLETED
Breast Cancer
Optimal Health Research
 2016-02 PHASE2; PHASE3
NCT02001766 UNKNOWN
Type 2 Diabetes
Anders Rasmussen Rinnov
 2013-02 PHASE1; PHASE2
NCT02375828 COMPLETED
Neonatal Diabetes Secondary to Mutation in the Potassium Channel
Assistance Publique - Hôpitaux de Paris
 2015-03-20 PHASE3
NCT01855373 COMPLETED
Blood Sugar; Endothelial Function
Supplement Formulators, Inc.
 2012-07
NCT02279511 COMPLETED
Alzheimer's Disease
Sara Varea
 2014-12 PHASE2
NCT01499069 COMPLETED
Overactive Bladder
Samsung Medical Center
 2010-02
NCT02093611 COMPLETED
Muscle Fatigue Caused by Repetitive Muscle Exercise
Metabolic Technologies Inc.
 2013-07
NCT02039999 COMPLETED
Cough
Hull University Teaching Hospitals NHS Trust
 2015-02
NCT02217605 COMPLETED
Healthy
Stephen Bawden
 2011-03
NCT01414166 TERMINATED
Dyslipidemia
Merck Sharp & Dohme LLC
 2011-09 PHASE3
NCT01456650 COMPLETED
Type 2 Diabetes
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
 2011-03 PHASE4
NCT01508338 COMPLETED
Healthy Experienced Weight Training Males
Metabolic Technologies Inc.
 2012-01
NCT00617578 COMPLETED
Ventricular Tachycardia, Monomorphic
Biotronik SE & Co. KG
 2007-11 PHASE4
NCT01437943 TERMINATED
Kidney Disease; Kidney Failure, Chronic
Brigham and Women's Hospital
 2010-04 PHASE4
NCT01141504 COMPLETED
Healthy Subjects
Metabolic Technologies Inc.
 2010-06 PHASE1
NCT00917696 COMPLETED
Osteoarthritis Pain
Merck Sharp & Dohme LLC
 2009-10 PHASE1
NCT01130428 COMPLETED
Osteoporosis
Maastricht University Medical Center
 2010-10 PHASE1; PHASE2
NCT00610038 COMPLETED
Diabetes Mellitus
Assistance Publique - Hôpitaux de Paris
 2006-07 PHASE2
NCT01045486 WITHDRAWN
Atopic Dermatitis
Soonchunhyang University Hospital
 2010-01
NCT03121040 COMPLETED
Sports Injury
Shanghai Meiji Health Science and Technology Co., Ltd.
 2009-05-02
NCT01145092 COMPLETED
Type 2 Diabetes Mellitus; Insulin Resistance
Landsteiner Institut
 2006-02
NCT00481598 COMPLETED
Type 1 Diabetes Mellitus
Landsteiner Institut
 2006-01
NCT00710008 COMPLETED
Type 2 Diabetes Mellitus
Landsteiner Institut
 2006-02
NCT00147290 COMPLETED
Tachycardia, Ventricular; Ventricular Fibrillation
Medtronic Cardiac Rhythm and Heart Failure
 2004-02 PHASE4
NCT00147277 COMPLETED
Tachycardia, Ventricular; Ventricular Fibrillation
Medtronic Cardiac Rhythm and Heart Failure
 2004-03 PHASE4
NCT00159315 COMPLETED
Asthma; COPD; Smoking
Imperial College London
 2002-10
NCT00092586 COMPLETED
Hypercholesterolemia
Organon and Co
 2002-09 PHASE3
NCT00551447 COMPLETED
Coronary Disease
Organon and Co
 2002-01 PHASE3
NCT00014248 COMPLETED
Cachexia; Unspecified Adult Solid Tumor, Protocol Specific
Dartmouth-Hitchcock Medical Center
 2000-10 PHASE1
NCT00565188 COMPLETED
Cancer; Palliative Care; Survival; Quality of Life
Maastricht University Medical Center
 2002-03 PHASE3
NCT00212030 COMPLETED
Acute Myocardial Infarction
National Cerebral and Cardiovascular Center, Japan
 2001-10
NCT00654173 COMPLETED
Hypercholesterolemia
AstraZeneca
 2002-06 PHASE3
NCT00137462 COMPLETED
Hyperlipidemia
Pfizer
 2004-11 PHASE3
NCT00311987 TERMINATED
Hypercholesterolemia
Johns Hopkins University
 2006-04 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-09-04)

Check the ATP disodium product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an essential purine nucleoside triphosphate, ATP disodium serves as a crucial phosphate donor for protein kinases and a substrate for ATP-dependent enzymes, driving cellular signal transduction cascades and metabolic energy transfer. By maintaining intracellular energy homeostasis and modulating purinergic signaling, ATP disodium supports vital cellular functions such as motility, protein synthesis, and metabolic regulation, which is highly relevant to therapeutic strategies targeting neurodegenerative disorders like Alzheimer's disease and metabolic syndromes.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.